NTT-CORPORATION
6.9.2022 11:41:37 CEST | Business Wire | Press release
NTT Corporation (NTT, Head office: Chiyoda-ku Tokyo; President & CEO: Akira Shimada) has developed a digital coherent signal processing circuit and optical device that achieves the world's largest capacity of 1.2 Tbit/s per wavelength for optical transmission, which is 1.5 times faster than before. With this development, NTT tackles the challenge of achieving advanced optical transmission technology that can economically and significantly expand the capacity of existing systems while reducing the power consumption of communication devices.
The technology has also achieved the world’s highest optical signal modulation speed of 140 Giga baud and enables double the previous world record optical transmission distance of 800 Gbit/s. As a result, the capacity of optical transmission systems will increase by 12 times and the power consumption per bit will be reduced to 10% of the widely used commercial system. The improvements in the performance and power consumption of optical transmission systems should contribute to the All-Photonics Network foundational to the IOWN1 concept.
Our digital coherent signal processing circuit combines cutting-edge coded modulation with transmission performance approaching the theoretical limit and newly developed forward error correction that can correct bit errors in large amounts of data with low power consumption. This results in flexible coded modulation that maximizes the potential of high-speed optical devices. Furthermore, by utilizing a power-efficient algorithm to equalize signal distortion in the optical fiber transmission channel and the advanced CMOS processes, we have achieved a digital signal processing of 1.2 Tbit/s per wavelength with low power consumption.
The transceiver consists of a cutting-edge digital coherent signal processing circuit and a 140-Giga baud class optical device with the world's widest-class opto-electrical response bandwidth. In our approach, by increasing the modulation speed from 100 Giga baud to 140 Giga baud, higher resistance to waveform distortion and optical amplification noise caused by transmission could be achieved. As a result, the previous record transmission distance of 800 Gbit/s signals can be extended by more than twice that of the 100 Giga baud devices.
Toward the development of IOWN, NTT aims to create an innovative network with high capacity, low latency, flexibility, and low power consumption by continuing to expand and develop end-to-end photonics technology. We will promote the creation of economical, large-capacity, low-power-consumption networks by leveraging advanced optical transmission systems based on innovative technology. We also intend to collaborate with both international and domestic partners so that our developments can be valuable and beneficial for communities worldwide. You can access the full report about this development here.
1 IOWN: https://group.ntt/jp/newsrelease/2019/05/09/190509b.html (Japanese)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220905005467/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wyss Geneva Steps Into Its Next Chapter11.6.2026 13:33:00 CEST | Press release
Dr. Tracy Laabs named Director; Prof. Dr. Erwin Böttinger honored for his transformative leadership The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simult
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 13:24:00 CEST | Press release
Nearly two-thirds of patients aged 80+ treated with BRUKINSA remained progression-free at six years, despite advanced age and high-risk featuresNew European patient research reveals safety, disease severity, and effectiveness are the top drivers for first-line CLL treatment decisions – not time on therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D.,
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 13:00:00 CEST | Press release
Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib Safety profile was consistent with previous studies with no new safety signals identified Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrate
Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 13:00:00 CEST | Press release
Transaction adds 31 CLOs and more than $5 billion of AUM, strengthening Clearlake Credit’s position in liquid credit Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction
L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 12:30:00 CEST | Press release
Partnership brings together LTTS’ expertise in its Sustainability segment and the Databricks platform to accelerate Engineering Intelligence across industrial operations. L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
